

MATERIAL CHANGE NOTICE SUBMISSION DETAILS

MCN Number	2025-12-24-1460
OHCA Review Start Date	January 7, 2026
Anticipated date (unless tolled per regulation) by which OHCA could waive cost and market impact review	February 23, 2026
Anticipated date (unless tolled per regulation) by which OHCA could determine cost and market impact review required	March 9, 2026

SUBMITTER

HEALTH CARE ENTITY CONTACT FOR PUBLIC INQUIRY

Title	VP of Finance
First Name	Mary Jane
Last Name	Abalos
Email Address	mjabalos@fulgentgenetics.com
Street Address	1111 South Freeport Parkway
City	Coppell
State	Texas
Postal Code	75019

GENERAL

Business Name	Inform Diagnostics, Inc.
Website	https://www.informdx.com/
Ownership Type	Corporation
Other Ownership	
Tax Status	For-profit
Federal Tax ID	62-1637129
Description of Submitting Organization	See new folder/document "Section 3(h) - Description of Submitting Organization." Please also reference Section 6(a) (Description of the Transaction).
Health Care Provider	Yes
For Providers: Desc. of Capacity or Patients served in California	<p>Please also reference Section 9 (Services Provided Currently and Post Transaction)</p> <p>Inform Diagnostics, Inc. (InformDx) is an anatomic pathology laboratory specializing in dermatopathology, hermatopathology, breast, urologic, and molecular diagnostics. InformDx owns and operates three licensed laboratories in California, currently employs 7 personnel in California (Fulgent Genetics, Inc. maintains 351 California FTEs), and provides services primarily to Southern California. InformDx does not track the number of laboratory client-patients receiving laboratory services, but on a</p>

	consolidated revenue basis California represents approximately 14% of Fulgent Genetics, Inc, and its subsidiaries revenues.
For Payers: Enrollees per county	

LOCATIONS

Counties	Los Angeles; Orange; Riverside; San Bernardino; San Diego; San Luis Obispo; Santa Barbara; Ventura
California licenses and numbers	See new folder/document "Section 4(e)_InformDx California Health Care Licenses"
Other States Served	AK; AL; AR; AZ; CO; CT; DC; DE; FL; GA; HI; IA; ID; IL; IN; KS; KY; LA; MA; MD; ME; MI; MN; MO; MS; MT; NC; ND; NE; NH; NJ; NM; NV; NY; OH; OK; OR; PA; RI; SC; SD; TN; TX; UT; VA; VT; WA; WI; WV; WY
Other state(s) licenses and numbers	All other states where InformDx operates with licenses including Laboratory, CLIA, and required applicable state licenses.
Primary Languages used when providing services	English
Other language if not listed above	

MATERIAL CHANGE

ADDITIONAL ENTITIES

Business Name	Description of the Organization	Ownership Type	Additional MCN Submission
---------------	---------------------------------	----------------	---------------------------

CRITERIA

A health care entity with annual revenue, as defined in section 97435(d) , of at least \$25 million or that owns or controls California assets of at least \$25 million, or;	Yes
A health care entity with annual revenue, as defined in section 97435(d) , of at least \$10 million or that owns or controls California assets of at least \$10 million and is a party to a transaction with any health care entity satisfying subsection (b)(1), or	Yes
A health care entity located in a designated primary care health professional shortage area in California, as defined in Part 5 of Subchapter A of Chapter 1 of Title 42 of the Code of Federal Regulations (commencing with section 5.1), available at data.hrsa.gov .	No
To determine if you are located in a primary health care professional shortage area, please visit here	

CIRCUMSTANCES FOR FILING

The proposed fair market value of the transaction is \$25 million or more and the transaction concerns the provision of health care services.	Yes
<p>The transaction involves a transfer or change in control, responsibility or governance of the Submitter. A transaction will directly or indirectly transfer control, responsibility, or governance in whole or in part of a material amount of the assets or operations of a health care entity to one or more entities if:</p> <p>(1) The transaction would result in the transfer of 25% or more of the voting power of the members of the governing body of a health care entity, such as by adding one or more members, substituting one or more members, or through any other type of arrangement, written or oral; or</p> <p>(2) The transaction would vest voting rights significant enough to constitute a change in control such as supermajority rights, veto rights, and similar provisions even if ownership shares or representation on a governing body are less than 25%;</p>	Yes

TRANSACTION DETAILS

Anticipated Date of Transaction Closure	3/31/2026
Description of the Transaction	<p>InformDx, Fulgent Therapeutics LLC, and Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Dermatopathology Experts, LLC, Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., and GBRL Consulting, LLC (collectively, Bako) have entered into definitive agreements pursuant to which, among other things, InformDx will (a) purchase all of the issued and outstanding equity interests of Dermatopathology Experts, LLC in exchange for the purchase price of \$12.5 million subject to price adjustments, as set forth in the Purchase and Sale Agreement (PSA), and (b) purchase substantially all of the assets and certain specified liabilities related to the diagnostic and therapeutic services of Bako Pathology Holdings Corp. and its subsidiaries in exchange for the purchase price of \$43 million subject to price adjustments, as set forth in the Asset Purchase Agreement (APA) (Bako Assets) (collectively, the Proposed Transaction). As a result of this strategic Proposed Transaction, Dermatopathology Experts, LLC will operate as a wholly owned subsidiary of InformDx, and the Bako Assets will be incorporated into the existing operations of InformDx or one of its subsidiaries.</p>

	Bako does not have a physical presence in California and its operations are limited to the acceptance of specimens from California patients which are processed by a non-California clinical laboratory. The Proposed Transaction will have minimal impact upon California or California patients. In the immediate term, California residents will have no changes to their laboratory providers as a result of the Proposed Transaction. The Proposed Transaction will allow InformDx to enhance its laboratory services by broadening product and service offerings, while expanding its national presence through a diverse client base and network of expert pathologists. The parties do not anticipate any impact upon reimbursement rates, care referral patterns, access to needed services, or quality of care.
Submitted to US Department of Justice or Federal Trade Commission?	No
Submitted to Other Agency?	Yes
Date of Submission	12/22/2025
To Whom Submitted	Scott Barnhard, Chief Counsel and Director of Consumer Protection, Office of the Attorney General, S
Description of Submission (Include Agency name(s) and State(s))	Indiana Office of the Attorney General
Subject to court proceeding	No
Description of current services provided and expected post-transaction impacts on health care services	See new folder/document "Section 9(a)_Services Provided Currently." Please also reference new folder/document "Section 3(h)_Description of Submitting Organization."
Prior mergers or acquisitions that: (A) involved the same or related health care services; (B) involved at least one of the entities, or their parents, subsidiaries, predecessors, or successors, in the proposed transaction; and (C) were closed in the last ten years.	Acquisition of CSI Laboratories by Fulgent: On August 9, 2021, Fulgent acquired CSI Laboratories, focused on cancer diagnostic testing for pathologists, community hospitals, and their patients. The total purchase price was approximately \$60 million, subject to adjustments. Acquisition of InformDx by Fulgent: On April 27, 2022, Fulgent acquired InformDx, a portfolio company of Avista Capital Partners, for a total purchase price of approximately \$170 million, subject to adjustments.

	<p>Acquisition of Fulgent Pharma Holdings, Inc. by Fulgent: On November 7, 2022, Fulgent acquired Fulgent Pharma, an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. The total purchase price was approximately \$100 million, subject to adjustments.</p> <p>Acquisition of ANP Technologies by Fulgent: On July 9, 2025, Fulgent acquired ANP Technologies, an innovation-driven company, which has developed multiple proprietary product platforms. The total purchase price was approximately \$22 million, subject to adjustments.</p>
<p>Description of Potential Post Transaction Changes</p>	<p>(i) Post-transaction, there will be no changes to the ownership, governance, or operational structure of InformDx. Dermatopathology Experts, LLC will operate as a wholly owned subsidiary of InformDx, and the Bako Assets will be incorporated into the existing operations of InformDx or one of its subsidiaries. There will be no post-transaction changes in the entities owning and holding applicable California licenses and permits nor any change in the services, leadership, or clinical or administrative staff of InformDx.</p> <p>As a consequence, the parties believe that the Proposed Transaction will not impact business line concentration or competition in the California market, and there is not expected to be any negative impact upon the availability, accessibility, or quality of health care services. The Proposed Transaction is not expected to result in the lessening of competition, creation of a monopoly, or entrenchment or extension of a dominant market position of any health care entity.</p> <p>(ii) InformDx currently employs 7 personnel in California and Fulgent maintains 351 California FTE. As a result of this transaction, neither InformDx nor Fulgent anticipate any changes to their California employee staffing levels, job security, retraining policies, wages, benefits, working conditions, and/or employment protections. Further, InformDx</p>

	<p>does not anticipate any changes to Dermatopathology Experts LLC current staffing levels, job security, or retraining policies or any negative impact on their wages, benefits, working conditions, or employment protections.</p> <p>(iii) There will be no post-transaction changes to any applicable city or county contracts held by InformDx or Fulgent regarding the provision of clinical laboratory services.</p> <p>(iv) Within 20 miles of each of InformDx's clinical laboratories are the following laboratories offering comparable health care services: (1) Inform Diagnostics, Inc. (Oceanside) – Tri-City Medical Center, Scripps Memorial Hospital Encinitas, Palomar Medical Center Escondido, and NeoGenomics; (2) InformDx (Anaheim) – UCI Health; Pathnostics, NeoGenomics, and St. Jude Medical; and (3) Cohen Dermatopathology, PC d/b/a Inform Diagnostics (Palm Desert) – Eisenhower Health, Desert Regional Medical Center, and John F. Kennedy Memorial Hospital, along with Quest Diagnostics, Labcorp, and other national chains and independent laboratories.</p>
<p>Description of the nature, scope, and dates of any pending or planned material changes occurring between the Submitter and any other entity, within the 12 months following the date of the notice</p>	<p>None.</p>

Section 3(h) - Description of Submitting Organization

[Please also reference Section 6(a) (Description of the Transaction)]

Inform Diagnostics, Inc. (InformDx) is nationally accredited anatomic pathology laboratory headquartered in Texas, specializing in dermatopathology, hematopathology, breast, urologic, and molecular diagnostics. InformDx emphasizes stringent quality assurance protocols, fellowship-trained pathologists, and advanced laboratory information systems to support timely and accurate diagnostic services. InformDx and its subsidiaries and affiliates operate in California and most other states, with three licensed and CLIA-accredited laboratories in California – Inform Diagnostics, Inc. (Oceanside); Lakewood Pathology Associates, Inc. d/b/a Inform Diagnostics (Anaheim); and; Cohen Dermatopathology, PC d/b/a Inform Diagnostics (Palm Desert). InformDx also has CLIA certified locations in Arizona, California, Maryland, Massachusetts, New York, Ohio, and Texas.

InformDx is a wholly owned subsidiary of California-headquartered Fulgent Genetics, Inc. and Fulgent Therapeutics LLC (collectively, Fulgent) which is a technology-based company with a well-established (1) laboratory services business and a (2) therapeutic development business. The laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. The therapeutic development business is focused upon developing drug candidates for treating a broad range of cancers utilizing a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and PK profile of new and existing cancer drugs.

InformDx is governed pursuant to a Delaware Certificate of Incorporation (see Section 12_Folder 9_Inform Diagnostics, Inc. – Charter.) Management of InformDx is pursuant to a Board of Directors who have authority to control, manage, and exercise all power of InformDx (see Section 12_Folder 9_Inform Diagnostics, Inc. – Bylaws). (Note that Caris Diagnostics, Inc. is the predecessor name of InformDx). Neither InformDx nor Fulgent Therapeutics LLC maintain any financials and consolidated financial statements/10-Ks are provided for Fulgent Genetics, Inc. for 2022-2024 (see Section 12_Folder 8). In that regard, revenues for 2024 were \$283 million, for 2023 \$289 million, and for 2022 \$619 million.

OHCA Material Change Notice – Inform Diagnostics, Inc.
Section 4(e) – California Health Care Licenses

Laboratory	License Type	ID Number	State of issue	Date issued	Expiration Date
Inform Diagnostics, Inc. (Anaheim)	Clinical and Public Health Laboratory License (CDPH)	CDF-00338461	California	06/29/2025	06/28/2026
Cohen Dermatopathology, PC - Inform Diagnostics (Palm Desert)	Clinical and Public Health Laboratory License (CDPH)	CLF-90015506	California	05/30/2025	05/29/2026
Inform Diagnostics, Inc. (Oceanside)	Clinical and Public Health Laboratory License (CDPH)	CLF-90014116	California	10/28/2025	10/27/2026

Section 9(a) Services Provided Currently

[Please also reference “Section 3(h)_Description of Submitting Organization.”]

Counties Where Services Are Currently Performed and Any Post-Transaction Changes Thereto

InformDx does not track the California county location of residents receiving InformDx’s laboratory testing services, but currently provides services to patients residing in Los Angeles, Orange, Riverside; San Bernardino, San Diego, San Luis Obispo, Santa Barbara, and Ventura counties along with several additional California counties. With the Proposed Transaction, the number of counties served by InformDx likely will remain the same.

Levels And Type Of Health Care Services Currently Offered

From its three California-based accredited laboratories, InformDx provides accurate and high-quality pathology laboratory services specializing in dermatopathology, hematopathology, breast, urologic, and molecular diagnostics.

Summary of the Number and Type Of Patients Currently Served and Any Post-Transaction Changes Thereto

InformDx has approximately 186 clients who utilize InformDx for the clinical laboratory testing requirements of client’s patients. InformDx does not track the number of client-patients receiving laboratory services. On a consolidated revenue basis, California represents approximately 14% of Fulgent and its subsidiaries revenues. While many client-patients receiving testing do not provide information regarding their demographics, InformDx provides laboratory services to a demographically diverse patient population, including individuals of all ages, genders, racial and ethnic backgrounds, preferred language, and disability status. InformDx supports a broad payor mix, encompassing commercial insurance, Medicare and Medicare Advantage plans, Medicaid and managed Medicaid programs, TRICARE, and self-pay arrangements. Other than expanding product and service offerings as a result of the Proposed Transaction, there will be no post-transaction changes to the number and type of client-patients served by InformDx.

Current Community Needs Assessments, Charity Care, and Community Benefit Programs, And Any Post-Transaction Changes Thereto

InformDx has not conducted any community needs assessments, but Fulgent maintains a financial assistance program and Genetics Access Program. The programs are designed to increase accessibility of genetic testing and reduce patient financial burden seeking to ensure that every patient has access to the essential information to make confident and informed decisions about their health. Further, Fulgent designs custom products and workflows for California clinics servicing low income and underserved communities.

Following the Proposed Transaction, there will be no changes to InformDx’s commitment to provide laboratory services (1) without regard to the patient’s age, race, color, creed, ethnicity,

religion, national origin, marital status, sex, sexual orientation, gender identity or expression, disability, veteran or military status, or payor source, (2) to individuals covered by Medicare, Medicaid, and other state or federal health care programs, and (3) along with charity care and community benefit programs.

Whether Medi-Cal and Medicare Patients Are Currently Accepted and Any Post-Transaction Changes Thereto

Yes, InformDx currently and will continue to provide laboratory services to Medi-Cal and Medicare eligible patients.

Section 9(a) Services Provided Currently (Fulgent Therapeutics, LLC)

[Please also reference “Section 3(h) Description of Submitting Organization”]

Counties Where Services Are Currently Performed and Any Post-Transaction Changes Thereto

Fulgent Therapeutics, LLC does not track the California county location of residents receiving Fulgent Therapeutics, LLC’s laboratory testing services, but currently provides services to patients residing in Los Angeles and Orange counties along with several additional California counties. With the Proposed Transaction, the number of counties served by Fulgent Therapeutics, LLC likely will remain the same.

Levels And Type Of Health Care Services Currently Offered

From its three California-based accredited laboratories, Fulgent Therapeutics, LLC provides clinical genetics testing services. Additionally, utilizing Next Generation Sequencing technology among other novel technologies, Fulgent Therapeutics is developing drug candidates for treating a broad range of cancers.

Summary of the Number and Type Of Patients Currently Served and Any Post-Transaction Changes Thereto

Fulgent Therapeutics, LLC has approximately 369 clients nationwide with 150 California clients utilizing Fulgent Therapeutics, LLC for the clinical laboratory genetic testing requirements of client’s patients. Fulgent Therapeutics, LLC does not track the number of client-patients receiving laboratory services. On a consolidated revenue basis, California represents approximately 14% of Fulgent Genetics, Inc. and its subsidiaries revenues. While many client-patients receiving testing do not provide information regarding their demographics, Fulgent Therapeutics, LLC provides laboratory services to a demographically diverse patient population, including individuals of all ages, genders, racial and ethnic backgrounds, preferred language, and disability status. Fulgent Therapeutics, LLC supports a broad payor mix, encompassing commercial insurance, Medicare and Medicare Advantage plans, Medicaid and managed Medicaid programs, TRICARE, and self-pay arrangements. Other than expanding product and service offerings as a result of the Proposed Transaction, there will be no post-transaction changes to the number and type of client-patients served by Fulgent Therapeutics, LLC.

Current Community Needs Assessments, Charity Care, and Community Benefit Programs, And Any Post-Transaction Changes Thereto

Fulgent Therapeutics, LLC has not conducted any community needs assessments, but Fulgent Genetics, Inc. maintains a financial assistance program and Genetics Access Program. The programs are designed to increase accessibility of genetic testing and reduce patient financial burden seeking to ensure that every patient has access to the essential information to make confident and informed decisions about their health. Further, Fulgent designs custom products and workflows for California clinics servicing low income and underserved communities.

Following the Proposed Transaction, there will be no changes to Fulgent Therapeutics, LLC's commitment to provide laboratory services (1) without regard to the patient's age, race, color, creed, ethnicity, religion, national origin, marital status, sex, sexual orientation, gender identity or expression, disability, veteran or military status, or payor source, (2) to individuals covered by Medicare, Medicaid, and other state or federal health care programs, and (3) along with charity care and community benefit programs.

Whether Medi-Cal and Medicare Patients Are Currently Accepted and Any Post-Transaction Changes Thereto

Yes, Fulgent Therapeutics, LLC currently and will continue to provide laboratory services to Medi-Cal and Medicare eligible patients.

Section 10 of Material Change Transaction Notice
Additional Entities Involved in the Transaction

Business Name	Fulgent Therapeutics LLC
Business Website	N/A (general website is https://fulgentgenetics.com)
Address: Street 1	4399 Santa Anita Avenue
Address: Street 2	
Address: City	El Monte
Address: State	California
Address: Postal Code	91731
Ownership Type	Limited Liability Company
Federal Tax ID Number	32-0400050
Business lines or segments	Provides clinical genetics laboratory testing services. Utilizing Next Generation Sequencing technology among other novel technologies, develops drug candidates for cancer treatment.
Governance and operational structure (including ownership of or by a health care entity)	Fulgent Therapeutics LLC is a wholly owned subsidiary of Fulgent Genetics and is governed pursuant to its single member California LLC Operating Agreement. Management of Fulgent Therapeutics LLC is vested in the sole member, Fulgent Genetics, Inc., who has authority to control, manage, and exercise all powers of Fulgent Therapeutics LLC
Current county or counties of operation	Los Angeles; Orange
Annual revenue for the past three years	Revenue 2024: \$283 million; Revenue 2023: \$289 million; Revenue 2022: \$619 million (all from Fulgent Genetics, Inc. on a consolidated basis)
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	Fulgent Therapeutics LLC owns and operates three licensed laboratories in California, two in Los Angeles County (CDF-00342581, CLF-90016601) and one in Orange County (CLF-89911273). Fulgent Therapeutics LLC does not track the number of client-patients receiving laboratory services, but on a consolidated revenue basis, California represents approximately 14% of Fulgent Genetics, Inc. and its subsidiaries revenues. English is the primary language utilized by Fulgent Therapeutics LLC.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	Bako Pathology, LP
Business Website	N/A
Address: Street 1	545 Madison Avenue
Address: Street 2	7 th Floor
Address: City	New York
Address: State	New York
Address: Postal Code	10022
Ownership Type	Limited Partnership
Federal Tax ID Number	81-0803770
Business lines or segments	N/A
Governance and operational structure (including ownership of or by a health care entity)	Bako Pathology, LP is governed by its general partner Bako Pathology GP LLC
Current county or counties of operation	N/A – This is a holding entity and does not engage in any health care operations.
Annual revenue for the past three years	N/A
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This is not a provider
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	Bako Pathology Holdings Corp
Business Website	N/A
Address: Street 1	6240 Shiloh Road
Address: Street 2	
Address: City	Alpharetta
Address: State	GA
Address: Postal Code	30005
Ownership Type	Corporation
Federal Tax ID Number	45-3675364
Business lines or segments	N/A
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors
Current county or counties of operation	N/A – This is a holding corporation and does not engage in any health care operations.
Annual revenue for the past three years	On a consolidated basis: 2022: \$76.5 million 2023: \$76.8 million 2024: \$74.1 million
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This is not a provider
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	BPA Holding Corp
Business Website	N/A
Address: Street 1	6240 Shiloh Road
Address: Street 2	
Address: City	Alpharetta
Address: State	GA
Address: Postal Code	30005
Ownership Type	Corporation
Federal Tax ID Number	45-3675364
Business lines or segments	N/A
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors.
Current county or counties of operation	N/A – This is a holding corporation and does not engage in any health care operations.
Annual revenue for the past three years	On a consolidated basis: 2022: \$76.5 million 2023: \$76.8 million 2024: \$74.1 million
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This entity is not a provider.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	Dermatopathology Experts, LLC
Business Website	N/A
Address: Street 1	6240 Shiloh Rd.
Address: Street 2	
Address: City	Alpharetta
Address: State	Georgia
Address: Postal Code	30005
Ownership Type	Limited Liability Company
Federal Tax ID Number	47-5116892
Business lines or segments	N/A
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors/members.
Current county or counties of operation	N/A – This is a holding corporation and does not engage in any health care operations.
Annual revenue for the past three years	N/A
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This entity is not a provider.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	Bakotic Pathology Associates LLC
Business Website	N/A
Address: Street 1	6240 Shiloh Rd.
Address: Street 2	
Address: City	Alpharetta
Address: State	Georgia
Address: Postal Code	30005
Ownership Type	Limited liability company
Federal Tax ID Number	33-1168930
Business lines or segments	Clinical and Anatomic Laboratory
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors/members.
Current county or counties of operation	All 50 states in United States
Annual revenue for the past three years	2022: \$57.4 million 2023: \$50.2 million 2024: \$50.8 million
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	Bako Pathology Associates operates CLIA licensed, CAP accredited clinical laboratories that are licensed and performed laboratory and pathology services and operates under the BakoDx brand, which comprise a dermatopathology and anatomic/clinical pathology platform that services all 50 states. Bako does not have a physical presence in California and its operations are limited to the acceptance of specimens from California residents, which are processed by an out-of-state (non-California) clinical laboratory. In 2024, Bako's services to California residents represented 5% of nationwide operations.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	Podceuticals LLC
Business Website	N/A
Address: Street 1	6240 Shiloh Rd.
Address: Street 2	
Address: City	Alpharetta
Address: State	Georgia
Address: Postal Code	30005
Ownership Type	Limited liability company
Federal Tax ID Number	27-4390069
Business lines or segments	This entity does not have any active operations
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors/members.
Current county or counties of operation	All 50 states
Annual revenue for the past three years	N/A
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This entity is not a provider.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No

Business Name	GBRL Consulting LLC
Business Website	N/A
Address: Street 1	6240 Shiloh Rd.
Address: Street 2	
Address: City	Alpharetta
Address: State	Georgia
Address: Postal Code	30005
Ownership Type	Limited liability company
Federal Tax ID Number	82-4857517
Business lines or segments	This entity does not have any active operations.
Governance and operational structure (including ownership of or by a health care entity)	This entity is governed by its officers and directors/members.
Current county or counties of operation	N/A
Annual revenue for the past three years	N/A
For providers only - summary of provider type (hospital, physician group, etc.), facilities owned or operated, service lines, number of staff, geographic service area(s), capacity (e.g., number of licensed beds) or patients served (e.g., number of patients per county) in California in the last year, and primary and threshold languages used to serve members of the public	N/A – This entity is not a provider.
Include business addresses, if known, of all new entities that will be formed as a result of the transaction	N/A
Will this organization be submitting an additional MCN?	No